Literature DB >> 20213325

Mesenchymal-to-epithelial transition determinants as characteristics of ovarian carcinoma effusions.

Sivan Elloul1, Olga Vaksman, Helene Tuft Stavnes, Claes G Trope, Ben Davidson, Reuven Reich.   

Abstract

The present study investigated the intracellular regulation of E-cadherin in ovarian carcinoma. E-cadherin expression and regulation by Snail and Pak1 were studied in ES-2 and OVCAR-3 ovarian cancer cells in vitro. Twist1, Zeb1 and Vimentin mRNA expression and HIF-1alpha protein expression were analyzed in 80 and 189 clinical specimens, respectively. OVCAR-3 cells incubated with an anti-E-cadherin antibody formed smaller and looser spheroids compared to controls. Snail silencing using Small Hairpin RNA in ES-2 cells reduced invasion and MMP-2 activity, with unaltered cellular morphology. Using dominant negative (DN) and constitutively active (CA) Pak1 constructs, we found that DN Pak1 ES-2 and OVCAR-3 clones had reduced attachment to matrix proteins, invasion and MMP-2 activity compared to CA and wild-type cells. DN Pak1 ES-2 cells also bound less to LP9 mesothelial cells. DN Pak1 OVCAR-3 cells had lower Vimentin levels. Snail expression was lower in cultured effusions compared to primary carcinomas, and was cytoplasmic rather than nuclear. Twist1 (P < 0.001), Zeb1 (P = 0.003) and Vimentin (P = 0.03) mRNA expression was significantly higher in solid metastases compared to primary carcinomas and effusions. HIF-1alpha protein expression was lower in effusions compared to primary carcinomas and solid metastases (P = 0.033). Our data suggest that the previously reported E-cadherin re-expression in ovarian carcinoma effusions is regulated by Pak1. The transient nature of E-cadherin expression during ovarian carcinoma progression is probably the result of partial epithelial-to-mesenchymal transition (EMT) and the reverse process of mesenchymal-to-epithelial-like transition (MET). Expression of the EMT-related molecules Twist, Zeb1, Vimentin and HIF-1alpha is anatomic site-dependent in ovarian carcinoma.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20213325     DOI: 10.1007/s10585-010-9315-2

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  51 in total

1.  Regulation of tight junctions during the epithelium-mesenchyme transition: direct repression of the gene expression of claudins/occludin by Snail.

Authors:  Junichi Ikenouchi; Miho Matsuda; Mikio Furuse; Shoichiro Tsukita
Journal:  J Cell Sci       Date:  2003-03-26       Impact factor: 5.285

Review 2.  Tumor metastasis: a new twist on epithelial-mesenchymal transitions.

Authors:  Ann E Vernon; Carole LaBonne
Journal:  Curr Biol       Date:  2004-09-07       Impact factor: 10.834

3.  Loss of E-cadherin expression in melanoma cells involves up-regulation of the transcriptional repressor Snail.

Authors:  I Poser; D Domínguez; A G de Herreros; A Varnai; R Buettner; A K Bosserhoff
Journal:  J Biol Chem       Date:  2001-04-25       Impact factor: 5.157

Review 4.  Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?

Authors:  Héctor Peinado; David Olmeda; Amparo Cano
Journal:  Nat Rev Cancer       Date:  2007-05-17       Impact factor: 60.716

5.  The SLUG zinc-finger protein represses E-cadherin in breast cancer.

Authors:  Karen M Hajra; David Y-S Chen; Eric R Fearon
Journal:  Cancer Res       Date:  2002-03-15       Impact factor: 12.701

6.  Pak1 phosphorylation of snail, a master regulator of epithelial-to-mesenchyme transition, modulates snail's subcellular localization and functions.

Authors:  Zhibo Yang; Suresh Rayala; Diep Nguyen; Ratna K Vadlamudi; Shiuan Chen; Rakesh Kumar
Journal:  Cancer Res       Date:  2005-04-15       Impact factor: 12.701

7.  E-cadherin cell-cell adhesion in ewing tumor cells mediates suppression of anoikis through activation of the ErbB4 tyrosine kinase.

Authors:  Hyung-Gyoo Kang; Jasmine M Jenabi; Jingsong Zhang; Nino Keshelava; Hiroyuki Shimada; William A May; Tony Ng; C Patrick Reynolds; Timothy J Triche; Poul H B Sorensen
Journal:  Cancer Res       Date:  2007-04-01       Impact factor: 12.701

8.  Cadherin expression in ovarian carcinoma and malignant mesothelioma cell effusions.

Authors:  Stine Sivertsen; Aasmund Berner; Claire W Michael; Carlos Bedrossian; Ben Davidson
Journal:  Acta Cytol       Date:  2006 Nov-Dec       Impact factor: 2.319

9.  Hypoxia attenuates the expression of E-cadherin via up-regulation of SNAIL in ovarian carcinoma cells.

Authors:  Tsutomu Imai; Akiko Horiuchi; Cuiju Wang; Kenji Oka; Satoshi Ohira; Toshio Nikaido; Ikuo Konishi
Journal:  Am J Pathol       Date:  2003-10       Impact factor: 4.307

10.  The transcription factor ZEB1 (deltaEF1) promotes tumour cell dedifferentiation by repressing master regulators of epithelial polarity.

Authors:  K Aigner; B Dampier; L Descovich; M Mikula; A Sultan; M Schreiber; W Mikulits; T Brabletz; D Strand; P Obrist; W Sommergruber; N Schweifer; A Wernitznig; H Beug; R Foisner; A Eger
Journal:  Oncogene       Date:  2007-05-07       Impact factor: 9.867

View more
  32 in total

1.  Guiding epithelial cell phenotypes with engineered integrin-specific recombinant fibronectin fragments.

Authors:  Ashley C Brown; Jessica A Rowe; Thomas H Barker
Journal:  Tissue Eng Part A       Date:  2010-12-12       Impact factor: 3.845

Review 2.  The ZEB/miR-200 feedback loop--a motor of cellular plasticity in development and cancer?

Authors:  Simone Brabletz; Thomas Brabletz
Journal:  EMBO Rep       Date:  2010-08-13       Impact factor: 8.807

3.  Differential vimentin expression in ovarian and uterine corpus endometrioid adenocarcinomas: diagnostic utility in distinguishing double primaries from metastatic tumors.

Authors:  Mohamed M Desouki; Sarah J Kallas; Dineo Khabele; Marta A Crispens; Omar Hameed; Oluwole Fadare
Journal:  Int J Gynecol Pathol       Date:  2014-05       Impact factor: 2.762

4.  Discoidin domain receptor 1 is a novel transcriptional target of ZEB1 in breast epithelial cells undergoing H-Ras-induced epithelial to mesenchymal transition.

Authors:  Minsoo Koh; Yunjung Woo; Rajeshwari R Valiathan; Hae Yoen Jung; So Yeon Park; Yong Nyun Kim; Hyeong-Reh Choi Kim; Rafael Fridman; Aree Moon
Journal:  Int J Cancer       Date:  2014-08-30       Impact factor: 7.396

Review 5.  Overcoming challenges of ovarian cancer stem cells: novel therapeutic approaches.

Authors:  Cristóbal Aguilar-Gallardo; Emily Cecilia Rutledge; Ana M Martínez-Arroyo; Juan José Hidalgo; Santiago Domingo; Carlos Simón
Journal:  Stem Cell Rev Rep       Date:  2012-09       Impact factor: 5.739

6.  Adhesion molecule protein signature in ovarian cancer effusions is prognostic of patient outcome.

Authors:  Geoffrey Kim; Ben Davidson; Ryan Henning; Junbai Wang; Minshu Yu; Christina Annunziata; Thea Hetland; Elise C Kohn
Journal:  Cancer       Date:  2011-08-25       Impact factor: 6.860

7.  Mesenchymal gene program-expressing ovarian cancer spheroids exhibit enhanced mesothelial clearance.

Authors:  Rachel A Davidowitz; Laura M Selfors; Marcin P Iwanicki; Kevin M Elias; Alison Karst; Huiying Piao; Tan A Ince; Michael G Drage; Judy Dering; Gottfried E Konecny; Ursula Matulonis; Gordon B Mills; Dennis J Slamon; Ronny Drapkin; Joan S Brugge
Journal:  J Clin Invest       Date:  2014-04-24       Impact factor: 14.808

Review 8.  E-cadherin's dark side: possible role in tumor progression.

Authors:  Fausto J Rodriguez; Laura J Lewis-Tuffin; Panos Z Anastasiadis
Journal:  Biochim Biophys Acta       Date:  2012-03-13

9.  TGFβ splicing and canonical pathway activation in high-grade serous carcinoma.

Authors:  Neriya Gutgold; Ben Davidson; Liora Jacobs Catane; Arild Holth; Ellen Hellesylt; Claes G Tropé; Anne Dørum; Reuven Reich
Journal:  Virchows Arch       Date:  2017-04-21       Impact factor: 4.064

10.  Autophagy inhibition promotes epithelial-mesenchymal transition through ROS/HO-1 pathway in ovarian cancer cells.

Authors:  Zhe Zhao; Jing Zhao; Jing Xue; Xinrui Zhao; Peishu Liu
Journal:  Am J Cancer Res       Date:  2016-10-01       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.